Odyssey Therapeutics, Inc.Odyssey Therapeutics, Inc.
ODTXOdyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company which develops medicines for autoimmune and inflammatory diseases. Its programs include OD-001, an oral small-molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, and OD-002, an oral small-molecule inhibitor of solute carrier family 15 member 4, or SLC15A4. The company was founded by Gary D. Glick, Melissa Merrick and David L. Pompliano in April 2021 and is headquartered in Boston, MA.
Market cap
$1BNo data
Revenue
No dataNo data
Net income
No dataNo data
Free cash flow
No dataNo data
Current assets greatly exceed current liabilities, giving Odyssey exceptional short-term liquidity and balance-sheet flexibility. Capital-return measures were uniformly negative this quarter, with invested capital weakest and asset turnover at zero.
As of 2026-06-30Market
Listed stock
ODTXPriceNasdaqLoading…Loading…1Y